Exavir Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Exavir Therapeutics is a private, pre-revenue biotech pioneering ultra-long-acting (ULA) antiviral prodrugs, primarily targeting HIV and hepatitis B. Its core technology modifies existing, proven antiretroviral drugs into prodrugs that release the active agent slowly, enabling dosing intervals of up to six months or longer. The company has validated its platform through a significant partnership with ViiV Healthcare (GSK) for its lead asset, VH-310, which is now in Phase 1. Exavir's strategy aims to address major unmet needs in adherence, access, and cost in global antiviral markets.

HIV/AIDSHepatitis B

Technology Platform

Proprietary prodrug technology designed to create ultra-long-acting versions of existing antiviral drugs, enabling dosing intervals of several months via injection.

Opportunities

The primary opportunity is to capture significant market share in the multi-billion dollar HIV treatment and prevention markets by offering best-in-class dosing convenience with intervals of 4-6 months or longer.

The platform also allows for expansion into other chronic viral infections like hepatitis B, where long-acting therapies are scarce.

Risk Factors

Key risks include clinical failure of the prodrug approach in humans, intense competition from large pharmaceutical companies with substantial resources in the long-acting HIV space, and dependence on partnership success and future fundraising to advance internal pipeline candidates.

Competitive Landscape

Exavir competes in the rapidly evolving long-acting antiviral space, dominated by ViiV Healthcare (cabotegravir) and Gilead. Its differentiation is the potential for even longer dosing intervals. However, it faces competition from other modalities, including implants and oral long-acting drugs in development by larger, well-capitalized rivals.

More companies in Small Molecule Drugs →More companies in United States →